Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 777

1.

Determining clinically meaningful decline in preclinical Alzheimer disease.

Insel PS, Weiner M, Mackin RS, Mormino E, Lim YY, Stomrud E, Palmqvist S, Masters CL, Maruff PT, Hansson O, Mattsson N.

Neurology. 2019 Jul 9. pii: 10.1212/WNL.0000000000007831. doi: 10.1212/WNL.0000000000007831. [Epub ahead of print]

PMID:
31289148
2.

A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?

Eratne D, Loi SM, Walia N, Farrand S, Li QX, Varghese S, Walterfang M, Evans A, Mocellin R, Dhiman K, Gupta V, Malpas CB, Collins S, Masters CL, Velakoulis D.

Aust N Z J Psychiatry. 2019 Jun 21:4867419857811. doi: 10.1177/0004867419857811. [Epub ahead of print]

PMID:
31220922
3.

Avoiding methodological bias in studies of amyloid imaging results disclosure.

Taswell C, Donohue C, Mastwyk MT, Louey AG, Giummarra J, Robertson J, Darby DG, Masters CL, Rowe CC.

Alzheimers Res Ther. 2019 Jun 4;11(1):52. doi: 10.1186/s13195-019-0495-y. No abstract available.

4.

Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease.

Fazlollahi A, Calamante F, Liang X, Bourgeat P, Raniga P, Dore V, Fripp J, Ames D, Masters CL, Rowe CC, Connelly A, Villemagne VL, Salvado O; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group.

J Magn Reson Imaging. 2019 May 30. doi: 10.1002/jmri.26810. [Epub ahead of print]

PMID:
31145515
5.

Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.

Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, Rutz S, Widmann M, Leinenbach A, Blennow K.

Clin Biochem. 2019 May 23. pii: S0009-9120(19)30488-6. doi: 10.1016/j.clinbiochem.2019.05.006. [Epub ahead of print]

6.

Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology.

Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, Stephens AW, Barthel H, Fripp J, Masters CL, Dinkelborg L, Salvado O, Villemagne VL, De Santi S.

Alzheimers Dement. 2019 Jun;15(6):807-816. doi: 10.1016/j.jalz.2019.02.005. Epub 2019 May 14.

PMID:
31101517
7.

COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Sohrabi HR, Peretti M, Lim YY, Weinborn M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM.

IBRO Rep. 2019 May 2;6:147-152. doi: 10.1016/j.ibror.2019.05.001. eCollection 2019 Jun.

8.

Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.

Bransby L, Lim YY, Ames D, Fowler C, Roberston J, Harrington K, Snyder PJ, Villemagne VL, Salvado O, Masters CL, Maruff P for the AIBL Research Group.

J Clin Exp Neuropsychol. 2019 Aug;41(6):591-600. doi: 10.1080/13803395.2019.1593949. Epub 2019 Mar 29.

PMID:
30924399
9.

The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease.

Franzmeier N, Ren J, Damm A, Monté-Rubio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodríguez Gómez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin J, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Grau S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, Falkai P, Perneczky R, Lee JH, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Salloway S, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M.

Mol Psychiatry. 2019 Mar 21. doi: 10.1038/s41380-019-0404-6. [Epub ahead of print]

PMID:
30899092
10.

Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.

Vöglein J, Paumier K, Jucker M, Preische O, McDade E, Hassenstab J, Benzinger TL, Noble JM, Berman SB, Graff-Radford NR, Ghetti B, Farlow MR, Chhatwal J, Salloway S, Xiong C, Karch CM, Cairns N, Mori H, Schofield PR, Masters CL, Goate A, Buckles V, Fox N, Rossor M, Chrem P, Allegri R, Ringman JM, Höglinger G, Steiner H, Dieterich M, Haass C, Laske C, Morris JC, Bateman RJ, Danek A, Levin J; Dominantly Inherited Alzheimer Network.

Brain. 2019 May 1;142(5):1429-1440. doi: 10.1093/brain/awz050.

PMID:
30897203
11.

Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.

Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS.

Alzheimers Dement (Amst). 2019 Feb 22;11:180-190. doi: 10.1016/j.dadm.2018.12.008. eCollection 2019 Dec.

12.

ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes.

Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, Li QX, Collins SJ, Carlsson C, Asthana S, Masters CL, Johnson S, Morris JC, Albert M, Gross AL.

Neurology. 2019 Apr 2;92(14):e1567-e1579. doi: 10.1212/WNL.0000000000007248. Epub 2019 Mar 6.

PMID:
30842300
13.

To What Extent Does Age at Death Account for Sex Differences in Rates of Mortality From Alzheimer Disease?

Buckley RF, Waller M, Masters CL, Dobson A.

Am J Epidemiol. 2019 Jul 1;188(7):1213-1223. doi: 10.1093/aje/kwz048.

PMID:
30824901
14.

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease.

Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A.

Sci Adv. 2019 Feb 6;5(2):eaau7220. doi: 10.1126/sciadv.aau7220. eCollection 2019 Feb.

15.

Klotho allele status is not associated with Aβ and APOE ε4-related cognitive decline in preclinical Alzheimer's disease.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM.

Neurobiol Aging. 2019 Apr;76:162-165. doi: 10.1016/j.neurobiolaging.2018.12.014. Epub 2019 Jan 6.

PMID:
30716541
16.

Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study.

Villemagne VL, Velakoulis D, Doré V, Bozinoski S, Masters CL, Rowe CC, Walterfang M.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1132-1138. doi: 10.1007/s00259-019-4273-7. Epub 2019 Jan 28.

PMID:
30690666
17.

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.

Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M; Dominantly Inherited Alzheimer Network.

Nat Med. 2019 Feb;25(2):277-283. doi: 10.1038/s41591-018-0304-3. Epub 2019 Jan 21.

PMID:
30664784
18.

Creutzfeldt-Jakob disease surveillance in Australia: update to December 2016.

Klug GM, Sarros S, Stehmann C, Simpson M, McLean C, Masters CL, Collins SJ.

Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00023-4. Epub 2018 Dec 17.

19.

A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease.

Porter T, Burnham SC, Savage G, Lim YY, Maruff P, Milicic L, Peretti M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Taddei K, Groth D, Verdile G, Villemagne VL, Laws SM.

Front Aging Neurosci. 2018 Dec 19;10:423. doi: 10.3389/fnagi.2018.00423. eCollection 2018.

20.

Seizures as an early symptom of autosomal dominant Alzheimer's disease.

Vöglein J, Noachtar S, McDade E, Quaid KA, Salloway S, Ghetti B, Noble J, Berman S, Chhatwal J, Mori H, Fox N, Allegri R, Masters CL, Buckles V, Ringman JM, Rossor M, Schofield PR, Sperling R, Jucker M, Laske C, Paumier K, Morris JC, Bateman RJ, Levin J, Danek A; Dominantly Inherited Alzheimer Network.

Neurobiol Aging. 2019 Apr;76:18-23. doi: 10.1016/j.neurobiolaging.2018.11.022. Epub 2018 Dec 5.

PMID:
30616208
21.

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.

Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Jucker M, Masters CL, Rossor MN, Ringman JM, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Dominantly Inherited Alzheimer Network; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2018 Dec;10(12). pii: e9712. doi: 10.15252/emmm.201809712.

22.

Characterization of the metal status of natively purified alpha-synuclein from human blood, brain tissue, or recombinant sources using size exclusion ICP-MS reveals no significant binding of Cu, Fe or Zn.

Lothian A, Lago L, Mukherjee S, Connor AR, Fowler C, McLean CA, Horne M, Masters CL, Cappai R, Roberts BR.

Metallomics. 2019 Jan 23;11(1):128-140. doi: 10.1039/c8mt00223a.

PMID:
30465671
23.

Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Li QX, Ames D, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM; AIBL Research Group.

J Alzheimers Dis. 2018;66(3):1193-1211. doi: 10.3233/JAD-180713.

PMID:
30412495
24.

Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing.

Rainey-Smith SR, Gu Y, Gardener SL, Doecke JD, Villemagne VL, Brown BM, Taddei K, Laws SM, Sohrabi HR, Weinborn M, Ames D, Fowler C, Macaulay SL, Maruff P, Masters CL, Salvado O, Rowe CC, Scarmeas N, Martins RN.

Transl Psychiatry. 2018 Oct 30;8(1):238. doi: 10.1038/s41398-018-0293-5.

25.

A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer's Disease: The AIBL Active-Study.

Cox KL, Cyarto EV, Ellis KA, Ames D, Desmond P, Phal P, Sharman MJ, Szoeke C, Rowe CC, Masters CL, You E, Burrows S, Lai MMY, Lautenschlager NT.

J Alzheimers Dis. 2018 Oct 26. doi: 10.3233/JAD-180521. [Epub ahead of print]

PMID:
30372680
26.

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.

La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Doré V, Grinberg LT, Huang E, Hwang JH, Ikonomovic MD, Jack C Jr, Jagust WJ, Jin LW, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Lowe VJ, Masters CL, Mathis CA, McLean CL, Miller BL, Mungas D, O'Neil JP, Olichney JM, Parisi JE, Petersen RC, Rosen HJ, Rowe CC, Spina S, Vemuri P, Villemagne VL, Murray ME, Rabinovici GD.

Alzheimers Dement. 2019 Feb;15(2):205-216. doi: 10.1016/j.jalz.2018.09.001. Epub 2018 Oct 19.

PMID:
30347188
27.

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.

Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, Kiddle SJ, Batrla R, Blennow K.

Nat Rev Neurol. 2018 Nov;14(11):639-652. doi: 10.1038/s41582-018-0079-7. Review.

28.

Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults.

Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith SR, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P; AIBL Research Group.

Arch Clin Neuropsychol. 2018 Oct 1. doi: 10.1093/arclin/acy078. [Epub ahead of print]

PMID:
30272115
29.

Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease.

Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Fox NN, Graff-Radford NR, Levin J, Danek A, Vöglein J, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement. 2018 Nov;14(11):1427-1437. doi: 10.1016/j.jalz.2018.06.3059. Epub 2018 Sep 25.

PMID:
30266303
30.

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.

Araque Caballero MÁ, Suárez-Calvet M, Duering M, Franzmeier N, Benzinger T, Fagan AM, Bateman RJ, Jack CR, Levin J, Dichgans M, Jucker M, Karch C, Masters CL, Morris JC, Weiner M, Rossor M, Fox NC, Lee JH, Salloway S, Danek A, Goate A, Yakushev I, Hassenstab J, Schofield PR, Haass C, Ewers M.

Brain. 2018 Oct 1;141(10):3065-3080. doi: 10.1093/brain/awy229.

31.

Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults.

Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith S, Robertson J, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P; AIBL Research Group.

J Alzheimers Dis. 2018;65(4):1313-1325. doi: 10.3233/JAD-180507.

PMID:
30149452
32.

Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL.

Bourgeat P, Doré V, Fripp J, Ames D, Masters CL, Salvado O, Villemagne VL, Rowe CC; AIBL research group.

Neuroimage. 2018 Dec;183:387-393. doi: 10.1016/j.neuroimage.2018.08.044. Epub 2018 Aug 18.

PMID:
30130643
33.

Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease.

Baker JE, Lim YY, Jaeger J, Ames D, Lautenschlager NT, Robertson J, Pietrzak RH, Snyder PJ, Villemagne VL, Rowe CC, Masters CL, Maruff P.

J Alzheimers Dis. 2018;65(3):977-988. doi: 10.3233/JAD-180344.

PMID:
30103330
34.

Ocular Biomarkers of Alzheimer's Disease: The Role of Anterior Eye and Potential Future Directions.

Dehghani C, Frost S, Jayasena R, Masters CL, Kanagasingam Y.

Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3554-3563. doi: 10.1167/iovs.18-24694. Review.

PMID:
30025102
35.

Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease.

Harrington KD, Schembri A, Lim YY, Dang C, Ames D, Hassenstab J, Laws SM, Rainey-Smith S, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P; AIBL Research Group.

Neurobiol Aging. 2018 Oct;70:170-179. doi: 10.1016/j.neurobiolaging.2018.06.005. Epub 2018 Jun 11.

PMID:
30015036
36.

Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease.

Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, McDade E, Chhatwal J, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, Salloway S, Schofield P, Morris JC, Maruff P, Bateman RJ; Dominantly Inherited Alzheimer Network.

Ann Neurol. 2018 Sep;84(3):424-435. doi: 10.1002/ana.25299. Epub 2018 Aug 25.

PMID:
30014553
37.

Author Correction: Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.

Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC.

Nat Rev Neurol. 2018 Jul;14(7):446. doi: 10.1038/s41582-018-0021-z.

PMID:
29880829
38.

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.

Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Doré V, Dobson A, Masters CL, Waller M, Rowe CC, Maruff P, Donohue MC, Rentz DM, Kirn D, Hedden T, Chhatwal J, Schultz AP, Johnson KA, Villemagne VL, Sperling RA; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle study of ageing; Harvard Aging Brain Study.

Alzheimers Dement. 2018 Sep;14(9):1193-1203. doi: 10.1016/j.jalz.2018.04.010. Epub 2018 May 24.

PMID:
29803541
39.

Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study.

Weinborn M, Bucks RS, Sohrabi HR, Rainey-Smith SR, Brown BM, Gardener SL, Gozt A, Christensen D, Savage G, Laws SM, Taddei K, Maruff P, Robertson JS, Ellis KA, Ames D, Masters CL, Rowe CC, Martins RN.

Psychol Assess. 2018 Oct;30(10):1308-1316. doi: 10.1037/pas0000565. Epub 2018 May 21.

40.

Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography.

Brown BM, Rainey-Smith SR, Dore V, Peiffer JJ, Burnham SC, Laws SM, Taddei K, Ames D, Masters CL, Rowe CC, Martins RN, Villemagne VL.

J Alzheimers Dis. 2018;63(4):1299-1305. doi: 10.3233/JAD-170998.

PMID:
29758940
41.

White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.

Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Fӧrster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, Salloway S, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network.

PLoS One. 2018 May 9;13(5):e0195838. doi: 10.1371/journal.pone.0195838. eCollection 2018.

42.

Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.

Martins RN, Villemagne V, Sohrabi HR, Chatterjee P, Shah TM, Verdile G, Fraser P, Taddei K, Gupta VB, Rainey-Smith SR, Hone E, Pedrini S, Lim WL, Martins I, Frost S, Gupta S, O'Bryant S, Rembach A, Ames D, Ellis K, Fuller SJ, Brown B, Gardener SL, Fernando B, Bharadwaj P, Burnham S, Laws SM, Barron AM, Goozee K, Wahjoepramono EJ, Asih PR, Doecke JD, Salvado O, Bush AI, Rowe CC, Gandy SE, Masters CL.

J Alzheimers Dis. 2018;62(3):965-992. doi: 10.3233/JAD-171145. Review.

43.

Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years.

Bradfield NI, Ellis KA, Savage G, Maruff P, Burnham S, Darby D, Lautenschlager NT, Martins RN, Masters CL, Rainey-Smith SR, Robertson J, Rowe C, Woodward M, Ames D.

Alzheimer Dis Assoc Disord. 2018 Jul-Sep;32(3):190-196. doi: 10.1097/WAD.0000000000000252.

PMID:
29561277
44.

Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing.

Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS, Jack C Jr, Ances BM, Ringman JM, Marcus DS, Ghetti B, Farlow MR, Danek A, Levin J, Yakushev I, Laske C, Koeppe RA, Galasko DR, Xiong C, Masters CL, Schofield PR, Kinnunen KM, Salloway S, Martins RN, McDade E, Cairns NJ, Buckles VD, Morris JC, Bateman R, Sperling RA; Dominantly Inherited Alzheimer Network.

Brain. 2018 May 1;141(5):1486-1500. doi: 10.1093/brain/awy053.

45.

Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden.

Rainey-Smith SR, Mazzucchelli GN, Villemagne VL, Brown BM, Porter T, Weinborn M, Bucks RS, Milicic L, Sohrabi HR, Taddei K, Ames D, Maruff P, Masters CL, Rowe CC, Salvado O, Martins RN, Laws SM; AIBL Research Group.

Transl Psychiatry. 2018 Feb 26;8(1):47. doi: 10.1038/s41398-018-0094-x.

46.

Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.

Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, Dichgans M, Haass C, Suárez-Calvet M, Fagan AM, Paumier K, Benzinger T, Masters CL, Morris JC, Perneczky R, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Teipel S, Kilimann I, Ramirez A, Rossor M, Jucker M, Chhatwal J, Spottke A, Boecker H, Brosseron F, Falkai P, Fliessbach K, Heneka MT, Laske C, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Kofler B, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Weiner M, Lee JH, Salloway S, Danek A, Goate A, Schofield PR, Bateman RJ, Ewers M.

Brain. 2018 Apr 1;141(4):1186-1200. doi: 10.1093/brain/awy008.

47.

Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.

Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC.

Nat Rev Neurol. 2018 Apr;14(4):225-236. doi: 10.1038/nrneurol.2018.9. Epub 2018 Feb 16. Review. Erratum in: Nat Rev Neurol. 2018 Jul;14(7):446.

PMID:
29449700
48.

CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldt-Jakob disease diagnosis while transitioning to next generation diagnostics.

Li QX, Varghese S, Sarros S, Stehmann C, Doecke JD, Fowler CJ, Masters CL, Collins SJ.

J Clin Neurosci. 2018 Apr;50:292-293. doi: 10.1016/j.jocn.2018.01.064.

PMID:
29422367
49.

High performance plasma amyloid-β biomarkers for Alzheimer's disease.

Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li QX, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K.

Nature. 2018 Feb 8;554(7691):249-254. doi: 10.1038/nature25456. Epub 2018 Jan 31.

PMID:
29420472
50.

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.

Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Lancet Neurol. 2018 Mar;17(3):241-250. doi: 10.1016/S1474-4422(18)30028-0. Epub 2018 Feb 1.

Supplemental Content

Loading ...
Support Center